"10.1371_journal.pone.0044260","none","2012-09-24T00:00:00Z","Steven John Kiddle; Madhav Thambisetty; Andrew Simmons; Joanna Riddoch-Contreras; Abdul Hye; Eric Westman; Ian Pike; Malcolm Ward; Caroline Johnston; Michelle Katharine Lupton; Katie Lunnon; Hilkka Soininen; Iwona Kloszewska; Magda Tsolaki; Bruno Vellas; Patrizia Mecocci; Simon Lovestone; Stephen Newhouse; Richard Dobson; for the Alzheimers Disease Neuroimaging Initiative","National Institute of Health Research Biomedical Research Centre for Mental Health, South London and Maudsley National Health Service Foundation Trust, London, United Kingdom; Kings College London, Institute of Psychiatry, London, United Kingdom; Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland, United States of America; Proteome Sciences plc, Cobham, Surrey, United Kingdom; School of Neurology, University of Eastern Finland and University Hospital of Kuopio, Kuopio, Finland; Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Lodz, Poland; 3rd Department of Neurology, “G. Papanicolaou” Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece; Department of Geriatric Medicine, Grontople de Toulouse, Toulouse University Hospital, Toulouse, France; Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy","Conceived and designed the experiments: M. Thambisetty AS SL SN RD. Analyzed the data: SJK. Wrote the paper: SJK M. Thambisetty AS SN RD. APOE measurements in AddNeuroMed and DCR: JRC AH IP MW MKL KL. Input on image analysis: EW. Provided cluster computing support: CJ. AddNeuroMed clinical centre lead: HS IK M. Tsolaki BV PM.","Intellectual property has been registered on the use of plasma proteins for use as biomarkers for AD by Kings College London and Proteome Sciences, with SL and M. Thambisetty named as inventors. IP and MW were full-time employees of Proteome Sciences, London, United Kingdom, at the time of their contribution to the work described in this manuscript. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. Patent Title Methods and Compositions Relating to Alzheimers Disease Subject Covers utility of around 30 proteins, specifically listing 16 in the Dependent claims for diagnosis of Alzheimers disease Filing Proteome Sciences with Kings Business United Kingdom Priority GB0421639.6 dated 29/09/2004 PCT Application PCT/GB2005/003756 dated 29/09/2005 Application in Europe, Japan, United States, Australia, and Canada, dated 15/03/2007 to 16/10/2007. In addition Alzheimers Disease Neuroimaging Initiative recieved funding from: Abbott; Alzheimers Association; Alzheimers Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","09","Steven John Kiddle","SJK",20,TRUE,1,NA,1,2,TRUE,TRUE,TRUE,6,"3;15;17;18;19;20",TRUE
